7 December 2023 - Formycon, Polpharma Biologics, Bioeq and Teva Canada jointly announce that Health Canada has granted the Notice of Compliance for Ranopto (ranibizumab), a biosimilar to Lucentis, for the treatment of several serious retinal diseases in Canada.

Ranopto is indicated for the treatment of neovascular (wet) age-related macular degeneration, the treatment of visual impairment due to diabetic macular oedema or choroidal neovascularisation, as well as the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion.

Rerad Formycon press release